Smith & Nephew SNATS (SNN) Receives Coverage Optimism Rating of 0.13
News headlines about Smith & Nephew SNATS (NYSE:SNN) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Smith & Nephew SNATS earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 47.387811136639 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Will a 'Huge Tax Cut' Ease Burden for MedTech Players? (finance.yahoo.com)
- Critical Contrast: Smith & Nephew SNATS (SNN) and Its Peers (americanbankingnews.com)
- Critical Review: Smith & Nephew plc (SNN) & Its Competitors (americanbankingnews.com)
- Stocks Under Scanner in the Medical Equipment Space — ResMed, Smith & Nephew, Stryker, and Zimmer Biomet (bizjournals.com)
Smith & Nephew SNATS (NYSE SNN) traded down $0.01 during trading hours on Friday, hitting $35.78. 119,951 shares of the company were exchanged, compared to its average volume of 499,397. The company has a current ratio of 2.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Smith & Nephew SNATS has a 52 week low of $27.96 and a 52 week high of $40.43.
The business also recently declared a semiannual dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a $0.246 dividend. The ex-dividend date was Thursday, October 5th. This represents a dividend yield of 1.37%.
Several equities analysts have commented on SNN shares. Zacks Investment Research raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Wednesday, September 20th. BidaskClub raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 1st. Finally, Canaccord Genuity initiated coverage on shares of Smith & Nephew SNATS in a report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Smith & Nephew SNATS presently has an average rating of “Hold” and a consensus target price of $42.50.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/smith-nephew-snats-snn-receives-coverage-optimism-rating-of-0-13/1724590.html.
About Smith & Nephew SNATS
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.